Active Biotech Interim Report Q3 2024

MARKN.

THIRD QUARTER IN BRIEF

  • Active Biotech entered agreement with MD Anderson for a clinical study of tasquinimod in myelofibrosis (July 1)
  • Active Biotech provided an update on the clinical phase Ib/IIa study with tasquinimod in relapsed refractory multiple myeloma (July 15)
  • Active Biotech reported intriguing intraocular concentrations achieved in a clinical biodistribution study of laquinimod eye drops (September 10)
  • Active Biotech announced a rights issue (September 23)


EVENTS AFTER THE END OF THE PERIOD

  • Active Biotech adjusts the terms in the announced rights issue (October 2)


FINANCIAL SUMMARY

SEK MJul-SepJan-SepFull year

2024 20232024 20232023
Net sales-----
Operating profit/loss-8.1-10.6-29.5-33.7-46.5
Profit/loss after tax-8.0-10.6-29.1-33.3-45.8
Earnings per share (SEK)-0.02-0.04-0.08-0.13-0.17
Cash and cash equivalents (at close of period)

6.25.636.2


The report is also available at www.activebiotech.com

The information was submitted for publication, through the agency of the contact persons set out below, at 2024-10-21 22.30 CEST.

Datum 2024-10-21, kl 22:30
Källa MFN
Bifogade filer
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!